ArticleJournal of translational medicine2025
Impact of oral anaerobic bacteria on the tumor immune microenvironment and prognosis of oral cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Experimental Models and Nanotechnology-Based Platforms in Oral Squamous Cell Carcinoma: From Tumor Biology to Translational Applications.Pharmaceutics · 2026Review
- First Description of Oral Microbiota in Domestic Cats Affected by Oral Squamous Cell Carcinoma.Pathogens (Basel, Switzerland) · 2026Article
- Metabolic crosstalk between oral microbiota and the host in OSCC: emerging roles of microbial metabolites in tumor initiation and progression.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) accounts for > 90% of oral cancers and has a poor prognosis. The microbiota affects the tumor microenvironment and tumor immune responses; however, the relationship between specific bacterial compositions and tumor-infiltrating immune cells in OSCC remains unclear.
methodsThe microbial diversity and compositions of tumor, normal mucosa, and stool samples from 42 OSCC patients were examined using 16S rDNA sequencing. Bacterial sampling was performed preoperatively by swabbing the tumor surface and normal mucosa and scraping a deep portion of the tumor. Differences in bacterial compositions between samples were examined using a linear discriminant analysis effect size analysis. To investigate the functional states of T cells, tumor-infiltrating immune cells were isolated and subjected to flow cytometry. The relationships among specific bacterial compositions, clinicopathological factors, and tumor-infiltrating immune cells were examined and the potential of microbiota-targeted therapy for OSCC was assessed.
resultsMicrobial α-diversity was higher in tumors than in the normal mucosa. Based on the bacterial compositions of tumor surfaces, patients were classified into anaerobic bacteria-dominant Group A (n = 13) and aerobic bacteria-dominant Group B (n = 10). Group A had more advanced cancer stages (p = 0.0003), shorter recurrence-free survival (p = 0.004), and a higher frequency of exhausted PD-1
conclusionsThis is the first study to show a direct relationship between intratumoral anaerobic bacterial predominance and CD8⁺ T cell exhaustion in OSCC, suggesting a microbiota-dependent mechanism of immune dysfunction and disease progression. The bacteria scoring system has potential as a prognostic marker and guide for microbiota-targeted therapies to enhance anti-tumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.